Long-Term Safety of Growth Hormone Deficiency Treatment in Cancer and Sellar Tumors Adult Survivors: Is There a Role of GH Therapy on the Neoplastic Risk?

被引：4
作者：
Di Somma, Carolina [1 ,2 ]
Scarano, Elisabetta [1 ]
Arianna, Rossana [1 ]
Romano, Fiammetta [1 ]
Lavorgna, Mariarosaria [1 ]
Serpico, Domenico [1 ]
Colao, Annamaria [1 ,2 ]
机构：
[1] Univ Naples Federico II, Dept Clin Med & Surg, Endocrinol Diabet & Androl Unit, I-80131 Naples, Italy
[2] Univ Naples Federico II, UNESCO Chair Educ Hlth & Sustainable Dev, I-80131 Naples, Italy
来源：
JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 02期
关键词：
GH treatment; cancer risk; GHD; NONFUNCTIONING PITUITARY-ADENOMA; CHILDHOOD-CANCER; REPLACEMENT THERAPY; FACTOR-I; HYPOPITUITARY PATIENTS; SUBSEQUENT NEOPLASMS; 2ND NEOPLASMS; BRAIN-TUMORS; RADIATION-THERAPY; ENDOCRINE-SOCIETY;
D O I：
10.3390/jcm12020662
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Experimental studies support the hypothesis that GH/IGF-1 status may influence neoplastic tissue growth. Epidemiological studies suggest a link between GH/IGF-1 status and cancer risk. However, several studies regarding GH replacement safety in childhood cancer survivors do not show a prevalence excess of de novo cancers, and several reports on children and adults treated with GH have not shown an increase in observed cancer risk in these patients. The aim of this review is to provide an at-a-glance overview and the state of the art of long-term effects of GH replacement on neoplastic risk in adults with growth hormone deficiency who have survived cancer and sellar tumors.
引用
收藏
页数：15
相关论文
共 110 条
[1]  
Abdel R.O., EPIDEMIOLOGIC TRANSI
[2]   GH replacement in 1034 growth hormone deficient hypopituitary adults:: demographic and clinical characteristics, dosing and safety [J].
Abs, R ;
Bengtsson, BÅ ;
Hernberg-Ståhl, E ;
Monson, JP ;
Tauber, JP ;
Wilton, P ;
Wüster, C .
CLINICAL ENDOCRINOLOGY, 1999, 50 (06) :703-713
[3]   Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis [J].
Abs, Roger ;
Mattsson, Anders F. ;
Thunander, Maria ;
Verhelst, Johan ;
Goth, Miklos I. ;
Wilton, Patrick ;
Koltowska-Haggstrom, Maria ;
Luger, Anton .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (03) :297-305
[4]   Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis [J].
Alotaibi, Nawaf M. ;
Noormohamed, Nadia ;
Cote, David J. ;
Alharthi, Salman ;
Doucette, Joanne ;
Zaidi, Hasan A. ;
Mekary, Rania A. ;
Smith, Timothy R. .
WORLD NEUROSURGERY, 2018, 109 :487-+
[5]   Occurrence of Multiple Subsequent Neoplasms in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study [J].
Armstrong, Gregory T. ;
Liu, Wei ;
Leisenring, Wendy ;
Yasui, Yutaka ;
Hammond, Sue ;
Bhatia, Smita ;
Neglia, Joseph P. ;
Stovall, Marilyn ;
Srivastava, Deokumar ;
Robison, Leslie L. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3056-3064
[6]   GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence [J].
Arnold, J. R. ;
Arnold, D. F. ;
Marland, A. ;
Karavitaki, N. ;
Wass, J. A. H. .
CLINICAL ENDOCRINOLOGY, 2009, 70 (03) :435-438
[7]   GROWTH-HORMONE THERAPY AND TUMOR RECURRENCE - FINDINGS IN CHILDREN WITH BRAIN NEOPLASMS AND HYPOPITUITARISM [J].
ARSLANIAN, SA ;
BECKER, DJ ;
LEE, PA ;
DRASH, AL ;
FOLEY, TP .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1985, 139 (04) :347-350
[8]   Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood? [J].
Auer, Matthias K. ;
Stieg, Mareike R. ;
Hoffmann, Janis ;
Stalla, Guenter K. .
CLINICAL ENDOCRINOLOGY, 2016, 84 (06) :862-869
[9]   Consequences of growth hormone (GH) overexpression and GH resistance [J].
Bartke, A ;
Chandrashekar, V ;
Bailey, B ;
Zaczek, D ;
Turyn, D .
NEUROPEPTIDES, 2002, 36 (2-3) :201-208
[10]   The effect of hypopituitarism on life expectancy [J].
Bates, AS ;
VantHoff, W ;
Jones, PJ ;
Clayton, RN .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) :1169-1172
12345678910